These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 15765523)
1. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. Rockenstein E; Schwach G; Ingolic E; Adame A; Crews L; Mante M; Pfragner R; Schreiner E; Windisch M; Masliah E J Neurosci Res; 2005 Apr; 80(2):247-59. PubMed ID: 15765523 [TBL] [Abstract][Full Text] [Related]
2. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Masliah E; Rockenstein E; Adame A; Alford M; Crews L; Hashimoto M; Seubert P; Lee M; Goldstein J; Chilcote T; Games D; Schenk D Neuron; 2005 Jun; 46(6):857-68. PubMed ID: 15953415 [TBL] [Abstract][Full Text] [Related]
3. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Hashimoto M; Rockenstein E; Mante M; Crews L; Bar-On P; Gage FH; Marr R; Masliah E Gene Ther; 2004 Dec; 11(23):1713-23. PubMed ID: 15483670 [TBL] [Abstract][Full Text] [Related]
4. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. Rockenstein E; Mallory M; Hashimoto M; Song D; Shults CW; Lang I; Masliah E J Neurosci Res; 2002 Jun; 68(5):568-78. PubMed ID: 12111846 [TBL] [Abstract][Full Text] [Related]
5. Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Suzuki K; Iseki E; Togo T; Yamaguchi A; Katsuse O; Katsuyama K; Kanzaki S; Shiozaki K; Kawanishi C; Yamashita S; Tanaka Y; Yamanaka S; Hirayasu Y Acta Neuropathol; 2007 Nov; 114(5):481-9. PubMed ID: 17653558 [TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein-positive structures induced in leupeptin-infused rats. Nakajima T; Takauchi S; Ohara K; Kokai M; Nishii R; Maeda S; Takanaga A; Tanaka T; Takeda M; Seki M; Morita Y Brain Res; 2005 Apr; 1040(1-2):73-80. PubMed ID: 15804428 [TBL] [Abstract][Full Text] [Related]
7. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. Wakamatsu M; Ishii A; Ukai Y; Sakagami J; Iwata S; Ono M; Matsumoto K; Nakamura A; Tada N; Kobayashi K; Iwatsubo T; Yoshimoto M J Neurosci Res; 2007 Jun; 85(8):1819-25. PubMed ID: 17465029 [TBL] [Abstract][Full Text] [Related]
8. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758 [TBL] [Abstract][Full Text] [Related]
9. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360 [TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Wakabayashi K; Engelender S; Tanaka Y; Yoshimoto M; Mori F; Tsuji S; Ross CA; Takahashi H Acta Neuropathol; 2002 Mar; 103(3):209-14. PubMed ID: 11907799 [TBL] [Abstract][Full Text] [Related]
11. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925 [TBL] [Abstract][Full Text] [Related]
12. Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Gómez-Tortosa E; Gonzalo I; Newell K; García Yébenes J; Vonsattel P; Hyman BT Acta Neuropathol; 2002 May; 103(5):495-500. PubMed ID: 11935266 [TBL] [Abstract][Full Text] [Related]
13. The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain. Totterdell S; Hanger D; Meredith GE Brain Res; 2004 Apr; 1004(1-2):61-72. PubMed ID: 15033420 [TBL] [Abstract][Full Text] [Related]
14. Transgenic models of alpha-synuclein pathology: past, present, and future. Hashimoto M; Rockenstein E; Masliah E Ann N Y Acad Sci; 2003 Jun; 991():171-88. PubMed ID: 12846986 [TBL] [Abstract][Full Text] [Related]
15. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254 [TBL] [Abstract][Full Text] [Related]
18. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Schell H; Hasegawa T; Neumann M; Kahle PJ Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424 [TBL] [Abstract][Full Text] [Related]
19. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Tanji K; Mori F; Mimura J; Itoh K; Kakita A; Takahashi H; Wakabayashi K Acta Neuropathol; 2010 Aug; 120(2):145-54. PubMed ID: 20339856 [TBL] [Abstract][Full Text] [Related]
20. The role of alpha-synuclein in neurodegenerative diseases. Bennett MC Pharmacol Ther; 2005 Mar; 105(3):311-31. PubMed ID: 15737408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]